Rüschoff, Josef http://orcid.org/0000-0003-1467-8149
Kumar, George
Badve, Sunil
Jasani, Bharat
Krause, Emma
Rioux-Leclercq, Nathalie
Rojo, Federico
Martini, Maurizio
Cheng, Liang
Tretiakova, Maria
Mitchell, Catherine
Anders, Robert A.
Robert, Marie E.
Fahy, Darren
Pyle, Mike
Le, Quang
Yu, Limin
Glass, Benjamin
Baxi, Vipul
Babadjanova, Zulfia
Pratt, James
Brutus, Sergine
Karasarides, Maria
Hartmann, Arndt
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 10 January 2024
Revised: 20 March 2024
Accepted: 22 March 2024
First Online: 4 April 2024
Declarations
: The study was conducted in compliance with BMS Bioethics Policy (). The samples procured from Discovery Life Sciences were processed in accordance with all applicable EU and US regulations as specified on the company’s website ().
: Dr. Rüschoff has received support for travel and participation in advisory boards from Agilent, AstraZeneca, Bristol Myers Squibb, DSI, and Merck/MSD. Dr Badve has received grants or contracts from Agilent, Lilly, the National Institutes of Health (NIH), and the National Cancer Institute; consulting fees from Agendia, Dako-Agilent, Ventana, Roche, and Daiichi-Sankyo; and honoraria from Medscape, Targos-Discovery, and PER; and is the Director of the Indian Cancer Genome Atlas Foundation. Dr. Jasani has received consulting fees from Bristol Myers Squibb. Dr Rojo has received grants or contracts from AstraZeneca, Roche, and Pfizer; consulting fees and honoraria from Roche, AstraZeneca, Novartis, MSD, Bristol Myers Squibb, Lilly, Amgen, Astellas, Glaxo-Smith Kline, and Daiichi Sankyo; and support for meeting attendance and travel from MSD, Roche, and AstraZeneca. Dr Martini has received funding from the University of Washington and Bristol Myers Squibb. Dr Anders has received grants or contracts from BMS, RAPT Therapeutics, Stand Up2Cancer, the NIH, and Mark Foundation; consulting fees from Bristol Myers Squibb, Merck SD, and AstraZeneca; and support for attending meetings from Bristol Myers Squibb. Dr Robert has received consulting fees from Takeda Pharmaceuticals and Bristol Myers Squibb. Drs Babadjanova, Pratt, Karasarides, and Kumar are employees of, and hold stock in, Bristol Myers Squibb. Dr. Brutus is a former employee of PathAI and holds stock in PathAI. Dr Hartmann has received consulting fees from Bristol Myers Squibb, MSD, Roche, Cepheid, Qiagen, Janssen, AstraZeneca, Agilent, Eli Lilly, Phäon, Ipsen, Diaceutics, Illumina, Abbvie, and Nanostring; receives travel support/support for attending meetings for, and participates in, advisory boards for Bristol Myers Squibb, MSD, Roche, Cepheid, Qiagen, Janssen, AstraZeneca, Agilent, Lilly, Phäon, Ipsen, and Diaceutics; and has received other research support from AstraZeneca, Biocartis, Cepheid, Gilead, Illumina, Janssen, Nanostring, Novartis, Owkin, Qiagen, QUIP GmbH, Roche, and Sanofi. Drs Krause, Rioux-Leclercq, Cheng, Tretiakova, Mitchell and Yu, and Mr Fahy, Pyle, Le, Glass and Baxi have no competing interests to declare.